More than 50 genes are recurrently affected by somatic mutation in estrogen receptor positive 54 (ER+) breast cancer but prognostic effects have not been definitively established. Primary tumor 55 DNA was therefore subjected to targeted sequencing from 625 postmenopausal (UBC-TAM 56 series) and 328 premenopausal (MA12 trial) hormone receptor-positive (HR+) patients.
156
In 1128 samples passing quality control standards, considering only non-silent mutations, 17 157 genes were mutated at a rate greater than 5%, and 6 at a rate greater than 10%; PIK3CA was 158 the only gene mutated in greater than 20% of samples (Figure 1A) . The order from most 159 recurrent to least for the 10 most frequently mutated genes was: PIK3CA (41.1%), TP53 160 (15.5%), MLL3 (13.4%), MAP3K1 (12.0%), CDH1 (10.5%), MALAT1 (10.0%), GATA3 (9.1%), 161 MLL2 (8.7%), ARID1A (7.2%), and BRCA2 (6.6%). This list correlates well with previously 162 reported recurrently mutated genes. For example, the top 4 most significantly mutated genes in 163 the ER+ subset of TCGA breast project 3 were PIK3CA (24.3%), TP53 (14.6%), GATA3 (8.9%) 164 and MAP3K1 (6.2%). The overall average mutation rate was estimated as 3.3 per MB of coding 165 sequence (range: 0.5 to 13.8 mutations per MB, excluding samples with no mutations called). In 166 order to determine whether mutations in any gene pair were mutually exclusive or co-occuring in 167 this dataset, a pairwise Chi-squared or Fisher's exact test was performed. Mutations in PIK3CA 168 and MAP3K1 were significantly more likely to co-occur (after BH FDR correction) in TAM 169 dataset, and were near significance in MA12 although not after correction (p = 0.08). These 170 results are summarized in Supplementary Data 4.
172
Hotspot analysis 173 174
As anticipated 7 , mutations in PIK3CA at E542K, E545K, and H1047R were highly recurrent in 175 this study with 69/1259 (5.5%) E542K, 104 (8.3%) E545K, and 181 (14.4%) H1047R mutations 176 (Supplementary Figure 6C) . Mutations in the ligand binding domain of ESR1 (1.1%) were 177 extremely rare 3 (Supplementary Figure 6A) . To uncover novel hotspots in these data, both Chi-178 squared and Fisher's exact tests were performed using mutation frequencies from previous 179 sequencing studies as the expected values (see Methods for definition of multi-study MAF file)
180
( Supplementary Table 3 ). The most notable novel finding was in CBFB (Figure 1B) 
191
Somatic mutation association with PAM50-based intrinsic subtype
193
The PAM50 intrinsic subtype calls were obtained from previously published analyses to 194 compare their mutational profiles between UBC-TAM and the MA12 studies. In both studies 195 about half the patients had luminal A tumor. However, the MA12 cohort had a higher proportion 196 of non-luminal subtypes, with 19.8% HER2-E and 6.6% basal and fewer luminal B tumors 197 (25.1% versus 42.4%) (Figure 2A-B) . Age density plots by subtype serve to emphasize the 198 large difference in the median age between the two sample cohorts (43 versus 65), and also the 199 influence of age with respect to the intrinsic subtype incidence. Namely, in the younger MA12 200 cohort, there is a younger peak incidence with basal-like breast cancer than Luminal A disease 201 ( Figure 2D) . In contrast in the older UBC-TAM cohort, an influence of age on intrinsic subtype 202 was not observed (Figure 2C) . Relationships between intrinsic subtype and mutation patterns 203 were also explored, classifying mutation positive status as "non-silent", "missense", 204 nonsense/frame-shift (FS/NS) or FS/NS+splice site (Supplementary Data 5). The FDR 205 corrected p-value (q-value) took into account that 83 genes were examined. However, this level 206 of false discovery detection could be viewed as overly conservative in an exploratory analysis 207 and any gene mutation with q-value association of <0.2 was therefore considered reportable 9-208 11 . For MA12, non-silent TP53 mutation was highly subtype-associated because of the very 209 high incidence in non-luminal versus luminal subtypes. PIK3CA and MAP3K1 mutations were 210 associated with Luminal A disease in both cohorts (Supplementary Figure 7A ). Finally, there 211 was a strong association between Luminal B status and non-silent (Supplementary Figure 7B) 212 as well as FS/NS mutations in GATA3 (Supplementary Data 5, q value = 0.006). GATA3 213 mutations were present in 28-30% of Luminal B cases and less so in luminal A cases (5%).
214
Considering q values of <0.2 the associations between FS/NS and non-silent mutations in ATM 215 and Luminal B tumors in MA12 (8-13%) suggests that ATM loss is also a possible luminal B 216 driver (Supplementary Figure 7B ), at least in younger women (MA12). Relationships between 217 age and mutation incidence were therefore also explored (Supplementary Figure 7C) , with the 218 finding that both ATM mutation and GATA3 mutations were associated with an earlier age of 219 onset within the luminal B category (Figure 2E and 2F) . Finally, NF1 mutations were 220 associated with the HER2-enriched subtype in the UBC-Tam series, explaining the association 221 with poor outcomes (Supplementary Figure 7B ).
223
Survival analysis according to somatic mutation.
225
For the UBC-TAM Series (Figure 3A) , univariate analysis of favorable prognostic associations 226 for breast cancer specific survival (BCSS) were detected for non-silent mutations in MAP3K1,
227
ERBB3, XBP1 and PIK3CA (Figure 3B , Supplementary Data 6). Adverse prognostic effects 228 were observed for non-silent mutations in DDR1 and TP53, as well as for frame-shift and 229 nonsense (FS/NS) mutations in NF1. An analysis for recurrence free survival (RFS) produced 230 similar results, except for ARID1B, which was marginally associated with more favorable Figure 4B . Multiple testing corrections indicated none of these findings could be 240 considered significant 9-11 . However, in multivariate analysis, based on the uncorrected p value, 241 the prognostic effects of mutations in ErbB2, ErbB4, LTK FS/NS, MAP3K4, PIK3R1, RB1, RELN 242 and TGFB2 were independent of pathological stage and grade ( Figure 4B ).
244
Verification of Prognostic effects of Mutations in METABRIC data.
246
While few genes were significant in univariate analysis after multiple testing correction, they 247 provide valuable hypotheses for further testing and validation. We therefore sought additional 248 data in the public domain to further assess the uncorrected p value-based findings in our data 249 set. The METABRIC consortium have reported somatic mutations in cBioPortal 12 with co-250 reported detailed hormone receptor status, age at diagnosis (median age=64 years for ER+ 251 patients), mean follow up of >8 years and disease-specific outcome 13, 14 . This data set provided 252 the opportunity to conduct a validation exercise for overlapping genes in the two data sets. For 
263
Prognostic interactions between PIK3CA and MAP3K1.
265
Since PIK3CA and MAP3K1 mutations co-associate, the combined effect of non-silent 266 mutations in these genes was examined. Patients with tumors exhibiting both genes mutated 267 have a more favorable clinical course than either singly mutant cases or cases without either 268 gene mutated. While the prognostic effects were strongest in the UBC-TAM series, this result 269 was also reproduced in the METABRIC data (Figure 7E-F) .
271
Mutation Analyses for Uncommon Targetable Kinases.
273
Of the 83 genes analyzed, at least 8 are directly targetable with small molecules or antibodies 274 that are either FDA approved or in late-stage development (Figure 8) . Pre-existing data on 275 these mutations is summarized (Supplementary Data 7). PIK3CA is not further discussed here, 276 since the mutation spectrum is well-described and large therapeutic studies are already . A few mutations identified in ERBB4, MET, and PDGFRA have been previously reported but 291 those reported here have not been functionally tested.
293 294

Discussion
296
The landscape of recurrently mutated genes in ER+ breast cancer observed in this study is 297 consistent with reports where matched germline samples were available, indicating that our 298 variant filters were effective for somatic mutation detection in a research setting. Overall, 299 mutation rates were higher in our cohort (e.g., for PIK3CA, MLL3, MAP3K1) than the TCGA 300 cohort, but were also lower for a few specific genes (e.g., TP53 and GATA3). Due to higher 301 sequencing data coverage of recurrently mutated target genes than TCGA and the use of a 302 different hybrid capture reagent, we were likely able to detect mutations that were missed with 303 lower-depth exome or whole genome sequencing data. It is also possible that in some instances 304 we overestimated somatic mutation rates, due to the lack of matched normal samples and 305 imperfections in our germline polymorphism filtering. In particular, a significant number of 306 6 BRCA1 and BRCA2 mutations are likely de novo germline mutations that we would not be able 307 to easily distinguish from somatic mutations. Of the 117 non-silent BRCA1/2 mutations 308 observed (from 110/1128 patients; 7 patients had two hits) 74 were observed at a VAF greater 309 than 40% and 31 were greater 60%. Variants with VAFs this high are less likely to be somatic 310 given the general expectation of impure tumor samples and heterozygous mutations. Indeed,
311
the VAFs for BRCA1/2 non-silent mutations (mean=44.8%) were significantly higher than for 312 other genes (mean=36.4%, p = 6.96e-06). There were 8 known pathogenic (ENIGMA expert 313 reviewed) mutations according to a search of the BRCA Exchange database 314 (http://brcaexchange.org, Nov 12, 2017) and another 37 likely pathogenic (FS/NS) mutations. Of 315 the remaining, 4 were known benign according to expert review (ENIGMA), and 8 benign, 15 316 likely benign and 45 variants of unknown significance according to all public sources.
318
The discovery of a novel recurrent CBFB (core binding factor subunit beta) splice site mutation 319 in this cohort illustrates a limitation of exome capture reagents. The affected bases in exon 2 of 320 CBFB display reduced sequence coverage, possibly due to high GC content, in the breast 321 TCGA exome dataset ( Supplementary Figures 9-10 ). This site was mutated in at least 1.5% of 322 ER+ breast cancers sequenced, bringing the overall rate of CBFB mutations to nearly 6%, 323 which should drive further investigation of this gene in ER+ breast cancer pathogenesis. CBFB 324 functions as a subunit in a heterodimeric core binding transcription factor that interacts with 325 RUNX1 20 . Consistent with this model, CBFB mutants were mutually exclusive from RUNX1 326 mutants in this cohort with only a single sample harboring non-silent mutations in both CBFB 327 and RUNX1.
329
The UBC-TAM and MA12 studies revealed different lists of potentially prognostic mutations.
330
Prognostic effects are likely to be strongly affected by the use of systemic therapy as well as by 331 patient age at diagnosis. The UBC-TAM series is the simplest study to interpret from a drug 332 resistance perspective since the only systemic therapy was tamoxifen. Thus, the consistent 333 adverse effect of NF1 FS/NS mutation on prognosis is intriguing as this result is consistent with 334 results from an in vitro screen for tamoxifen resistance 21 . Understanding why only FS/NS 335 mutations predict poor outcome, rather than missense or other non-silent mutations, will require 336 further investigation. In contrast, PIK3R1 mutation emerged as a consistent poor prognosis 337 mutation from the MA12 analysis, with validation in METABRIC. The proposed favorable 338 prognostic effects of PIK3CA mutation were observed in the UBC-TAM series, but were not 339 found to be independent of stage and grade, and PTEN mutations were neutral.
341
According to our validation results, NF1, PIK3R1, MAP3K1, PIK3CA and TP53 are likely to be 342 prognostic drivers. In postmenopausal women treated with adjuvant endocrine therapy, DDR1,
343
PRKDC and XBP1 should be further studied and of these DDR1 is the strongest candidate 344 because it was significant despite strict false discovery correction. DDR1 is a collagen-binding 345 receptor expressed in epithelial cells that stabilizes E-cadherin-mediated intracellular 346 adhesion 22 . DDR1 mutations also occur in endometrial cancer 23 , acute leukemia 24 and lung 347 cancer 25 . Loss of DDR1 (DDR1-null mice) produces hyper-proliferation and abnormal branching 348 of mammary ducts, suggesting DDR1 is a breast tumor suppressor 26 . The relationship between 349 truncating mutations in NF1 and poor outcome is consistent with an siRNA screen for genes 350 whose loss generates tamoxifen resistance 21 . Mutations in PRKDC will potentially produce a 
361
In conclusion, we have successfully utilized clinically well-annotated, uniformly treated patient 362 samples using DNA from archival material greater than 20 years old that lacks a matched 363 normal to explore the prognostic effects encoded by the mutational landscape of ER+ breast 364 cancer. We were able to confirm our prospective hypothesis that MAP3K1 is associated with 365 indolent disease and TP53 with adverse outcomes. We also associated NF1 FS/NS mutations 366 with strong adverse effects on prognosis. Similarly, PIK3R1 mutations were associated with an 367 adverse prognosis in contrast to PIK3CA mutation. This suggests somatic mutations in these 368 two physically interacting gene products are not biologically equivalent with respect to PI3 369 kinase pathway activation and resistance effects. The possibility that the long tail of low 370 frequency mutation events in luminal type breast cancer may harbor multiple molecular 371 explanations for poor outcomes is an important finding that should spur collaborative efforts to 372 thoroughly screen thousands of properly annotated cases. Only after these iterative efforts of 373 proposing and confirming candidates will a clinically useful and comprehensive somatic 374 mutation-based classification of ER+ breast cancer emerge. In the meantime, functional studies 375 should be pursued to understand the biological effects of somatic mutations, prioritizing these 376 studies according to whether the mutations are driving an adverse prognostic effect.
378
Methods
380
For the UBC-TAM series, an institutional review board approved study was based on formalin- Supplementary Table 3 .
390
A meta-analysis of six existing published large-scale breast cancer sequencing studies 1-3, 5, 32, 33 391 was performed to identify genes with recurrent coding region somatic mutations in breast cancer 392 (Supplementary Data 1). Additional drug targets 34 and genes with relevance to breast cancer 393 from targeted sequencing 35 , copy-number studies 13 or knowledge relating to somatic or germline 394 mutations (e.g., BRCA1, BRCA2, ERBB2, ESR1 and PRLR) were also included. This resulted in 395 a final list of 83 breast-cancer-related genes ( Supplementary Table 1 ). These genes were 
402
Variant calling was performed with the Genome Modeling System as previously described 36 .
403
Specifically, sequence data were aligned to reference sequence build GRCh37 using BWA 37 404 and de-duplicated with Picard. SNVs and indels were detected using the union of samtools 38 405 and VarScan2 5 and annotated using Ensembl version 70. Variants were restricted to the coding 406 regions of targeted genes and filtered for false positives and germline polymorphisms against a 407 database of nearly 70,000 unmatched normals from the ExAC consortium, 1000 Genomes 39 , 408 NHLBI exomes 40 and TCGA data sets 3, 41 . A binomial probability model was then applied to the 409 variants using VAF and total coverage to determine a log-likelihood ratio of being a somatic 410 variant as previously described 42 (See Supplementary Methods) . After filtering, all remaining 411 variants were manually reviewed. To ensure that variants of known clinical relevance were not 412 missed by automated variant calling approaches, a knowledge-based variant calling strategy 413 was performed focused on the mutations in the Database of Curated Mutations 43 .
415
Patient groups were defined by mutation status or truncating mutation status for each gene.
416
Fisher's exact and Chi-squared tests were used for hotspot analysis, mutual exclusivity or co-417 occurrence, and other categorical clinical statistics (e.g., mutation status vs. intrinsic subtype) as 
573
A) The overall mutation recurrence rate ranged from 41.1% of samples for PIK3CA to 0.0% for 574 PIN1. The figure depicts non-silent mutations for all 1128 patients for the top 16 most 575 recurrently mutated genes (>5% recurrence). If a patient had multiple mutations it is colored 576 according to the "most damaging" mutation following the order presented in the Mutation Type 577 legend (vertical color bar). Mutations per MB were calculated using the total number of 578 mutations observed over the total exome space corresponding to the tiled space from "SeqCap 579 EZ Human Exome Library v2.0". A correction factor was applied for genes not assayed using 580 the expected number of additional mutations based on TCGA data. B) Mutation recurrence 581 rates (amino acid level) in this study were compared to previously reported mutation rates from 582 a multi-study MAF file of six reported breast cancer sequencing studies (Supplementary Data 583 1). An entirely novel mutation "hot spot" was discovered affecting the exon 2 splice (donor) site 584 of CBFB in at least 15 patients. Six different single nucleotide substitutions, insertions and 585 deletions were observed, all affecting either the first or second base of the donor splice site.
586
These mutations were most likely missed in previous studies because of a lack of sequencing 587 coverage due to the GC-rich nature of exons 1 and 2 of CBFB ( Supplementary Figures 9-10 ).
588
Such mutations are predicted to significantly alter the canonical donor site and result in either 
623
Extensive filtering and manual review reduced this list to 2104 putatively somatic variants.
624
Survival analysis was applied to non-silent and truncating gene mutation status versus overall 
